2023 World Conference on Lung Cancer (Posters)-EP08.02. Long-Term Efficacy and Safety of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for IIB-III NSCLC: A Retrospective Study

EP08.02. Long-Term Efficacy and Safety of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for IIB-III NSCLC: A Retrospective Study - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the long-term efficacy and safety of tislelizumab in combination with chemotherapy as neoadjuvant/adjuvant therapy for stage IIB-III non-small cell lung cancer (NSCLC). The study included 23 patients who received neoadjuvant tislelizumab combined with chemotherapy and adjuvant tislelizumab therapy between 2020-2022. The primary endpoint was the 2-year event-free survival (EFS) rate.<br /><br />The results showed that 20 patients received 3-4 cycles of neoadjuvant therapy, and 22 patients underwent successful surgery with a median interval of 33.5 days. Eighteen patients received adjuvant tislelizumab therapy with a median of 4 cycles. After a median follow-up of 21 months, the 2-year EFS rate was 76.2%, and the objective response rate (ORR) was 85%. The surgical rate was 95.65% with a 100% R0 resection rate. The pathological down-staging rate was 90.9%, and the major pathological response (MPR) rate was 72.7%. Immune-related adverse events included pruritus, dermatitis, and myelosuppression.<br /><br />The study concluded that neoadjuvant and adjuvant tislelizumab combined with chemotherapy showed long-term EFS benefit and tolerable adverse events in stage IIB-III NSCLC patients. These findings support the use of tislelizumab plus chemotherapy as a potential treatment option in this patient population.<br /><br />Overall, this study provides evidence for the effectiveness and safety of the combination therapy in improving outcomes for patients with locally advanced NSCLC. The results suggest that neoadjuvant and adjuvant tislelizumab combined with chemotherapy may be a viable treatment strategy for stage IIB-III NSCLC patients. Further research and clinical trials are needed to validate these findings and determine the optimal treatment approach in this population.

Asset Subtitle

Yang Cheng

Meta Tag

Speaker Yang Cheng

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

tislelizumab

chemotherapy

neoadjuvant therapy

adjuvant therapy

stage IIB-III

non-small cell lung cancer

NSCLC

event-free survival

objective response rate

surgical rate